Head-to-head evidence
orforglipron vs PEX168
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
orforglipron · Foundayo
Marketed by Eli Lilly
NCT05803421 · Phase 3 · completed
The study is randomized and active-controlled with a large sample of 2,749 participants, but it is open-label rather than blinded. Its primary endpoint is a hard clinical cardiovascular outcome; however, the comparison cannot be judged because no results are currently available.
Next expected readout: May 2027 · NCT07613307 (registry estimate)
PEX168
Developed by Jiangsu Hengrui Pharmaceuticals and partners
NCT02477969 · Phase 3 · status unknown
This was a randomized, triple-blind, placebo-controlled trial with 587 participants, testing PEX168 against placebo, both added to metformin, using change in HbA1c as the primary measure. A published report of the trial's results describes the primary endpoint as met, with substantially more PEX168 patients than placebo patients reaching HbA1c targets at 24 weeks.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · PEX168's landscape